Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Follow-up of patients with scleral implants for the treatment of presbyopia that elect to undergo laser vision correction enhancement

Poster Details

First Author: J.Katz USA

Co Author(s):                        

Abstract Details

Purpose:

To examine postoperative near visual acuity outcomes of eyes that have previously received VisAbility Micro Inserts (Refocus Group, Dallas, TX) for presbyopia correction and opted to undergo Laser Vision Correction to neutralize unwanted refractive error (i.e. hyperopia with or without astigmatism) to achieve better uncorrected near visual acuity.

Setting:

The Midwest Center for Sight Chicago, IL USA

Methods:

Eleven patients who had completed a previous IDE clinical trial in which they received either unilateral or bilateral Scleral Spacing Procedures (SSP) to improve near visual acuity elected to undergo Laser Vision Correction (LVC). Visual acuity was measured at baseline (pre-LVC), and followed through 6 months postop.

Results:

Twenty-two eyes of 11 patients that were implanted with VisAbility Micro Inserts and underwent LVC were followed for 6 months post-LVC enhancement surgery. The mean lines of improvement (UCNVA) were 3.1 (+1.59 SD, range; 1-5 lines) at 3 months and 2.9 (+1.25 SD, range; 1-5 lines) at 6 months post op. Pre-op, none of the patients were J1 or better (UCNVA), 14% (3/22) were J2 or better, and 18% (4/22) were J3 or better. For patient UCNVA at 6 months post-op, 55% (12/22) were J1 or better, 77% (17/22) were J2 or better, and 95% (21/22) were J3 or better.

Conclusions:

Examination of patients with VisAbility Micro Inserts that subsequently elect to undergo LVC suggests that the combination of procedures may provide significant improvement in near vision with corresponding reduction in the amount of refraction needed to achieve optimal UCNVA.

Financial Disclosure:

research is funded, fully or partially, by a competing company

Back to Poster listing